Subsequent sensitivity analyses, adjusting for confounders such as age, sex, and ACE inhibitor use, have confirmed that SGLT2 inhibitors are associated with a lower risk of AKI (i.e., they are kidney-safe) [27]. This evidence concerns the gene SLC5A2 and acute kidney injury.